Panel comprises methods for measuring the levels of the drugs Digoxin, Gentamicin, Theophylline, Carbamazepine, Phenytoin, Phenobarbital and Valproic acid in human serum or plasma
Seven automated therapeutic drug monitoring (TDM) methods have been released by Bayer Diagnostics for use on the Advia 1650 chemistry system as part of the company's ongoing programme of menu expansion for this high-capacity laboratory analyser.
The new TDM assay panel comprises methods for measuring the levels of the drugs Digoxin, Gentamicin, Theophylline, Carbamazepine, Phenytoin, Phenobarbital and Valproic acid in human serum or plasma.
Such measurements are useful in monitoring drug levels in the body so that appropriate levels of the drugs may be maintained.
Availability of these assays will benefit users of the Advia 1650 by allowing them to consolidate more of their routine workload on to a single automated platform.
The assays can be run in random access mode on the Advia 1650 alongside all other analytes on the system, enabling users to deliver an efficient and rapid testing service at the highly productive rate of up to 1650 tests per hour.
To save time in the laboratory, all the reagents are supplied in liquid-stable format ready for use, conveniently packaged in bar-coded wedges.
Use of micro-volume technology provides the additional benefit of outstanding reagent efficiency.
To enhance the cost-effectiveness of the assays, common six-level calibrators and tri-level controls are available from Bayer to work with all seven Advia 1650 TDM methods.
The assays are not subject to interference from triglycerides, haemolysis, bilirubin or other common cross-reactants. Carbamazepine, Phenytoin, Phenobarbital and Valproic Acid are all anti-epileptic drugs.
Digoxin is a cardiovascular drug, while Theophylline is used in the treatment and prevention of asthma. Gentamicin is an antibiotic.
